The company's fiscal second-quarter results were forgettable at best, but management had more positive news to report.

Affirms guidance of Adjusted EBITDA positivity in Q4 2025.

Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, today announced select preliminary unaudited financial results for the fourth quarter and year ended December 31, 2025, in line ...

Albanese won't forget that some of the lobbies went straight for his throat.

Hero MotoCorp has partnered with Valeo to develop Advanced Rider Assistance Systems (ARAS) for its two-wheelers ...

Estimated Q4 2025 Revenue of $28.8 million, an increase of 41%; Grew full-year revenue to an estimated $88.5 million, an increase of 24%; Affirms guidance of Adjusted EBITDA positivity in Q4 2025.

Right now, cannabis businesses operating legally under state law still can't deduct basic costs like rent, salaries or ...

New tool predicts who selects opposing political news beyond self-reports. Visual method reveals gaps between stated openness ...

With UK ACCA exams near, Indian students navigate preparation challenges. Kamal Chhabra of KC GlobEd offers insights on eligibility, exam strategies and more.  | Competitive Exams ...

Migrants will be able to cheat their way through English language tests under £800m plans by Labour to make the tests ...

Veterinary ophthalmologists bridge the gap between clinical surgery and comparative research, ensuring regulatory compliance ...

Study shows alpha brain wave frequency shapes how the brain integrates touch and vision to create the feeling that your body ...